Jeff Fairman - 27 Sep 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
VP, Research
Signature
/s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
27 Sep 2021
Net transactions value
-$115,801
Form type
4
Filing time
29 Sep 2021, 19:52:21 UTC
Previous filing
30 Aug 2021
Next filing
28 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $8,502 +4,750 +92% $1.79* 9,894 27 Sep 2021 Direct
transaction PCVX Common Stock Sale $120,624 -4,611 -47% $26.16 5,283 27 Sep 2021 Direct F1, F2
transaction PCVX Common Stock Sale $3,679 -139 -2.6% $26.47 5,144 27 Sep 2021 Direct F1
holding PCVX Common Stock 341,227 27 Sep 2021 By Fairman Family Trust
holding PCVX Common Stock 50,000 27 Sep 2021 By AF 2020 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -4,750 -6.6% $0.000000 67,595 27 Sep 2021 Common Stock 4,750 $1.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $25.415 to $26.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The shares subject to the option are fully vested and exercisable.